GEMoaB Monoclonals explained

GEMoaB Monoclonals
Type:	GmbH
Founder:	Gerhard Ehninger, Michael Bachmann
Foundation:	2011
Location:	Dresden, Germany
Key People:	Arnim Ehninger, Chief Scientific Officer (CSO), Gerhard Ehninger (CMO)^[1]
Industry:	Biotechnology Pharmaceutical
Products:	GEM333; GEM3PSCA; UniCAR-T-CD 123, UniCAR-T-PSMA
Revenue:	n.a.

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.^{[2] [3]} It was acquired by the new company AvenCell Therapeutics in 2021.^{[4] [5]}

Company background

See also: Chimeric antigen receptor T cell. To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.^[6]

Scientific and strategic board

The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).^[7]

Co-operations

Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.^[8]

Drugs currently under development

• GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML^{[9] [10]}
• GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours^[11]
• UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
• UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours

Literatur

• Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141., .
• Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. .
• Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095., .
• C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967,, .

See also

• Gene therapy
• DKMS

Notes and References

1. https://www.gemoab.com/leadership-team Leadership Team Leadership Team
2. https://www.gemoab.com/gemoab Get to know GEMoaB
3. News: GEMoaB Announces First Patient Apheresed in a Phase IA Study with Lead Product Candidate from Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias . chemie-link.de . 9 March 2020 . May 11, 2020.
4. Web site: Clinical-stage biopharma company targets hard-to-treat cancers . 2024-02-12 . AvenCell . en-US.
5. Web site: 2021-06-22 . Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company . 2024-02-12 . Blackstone . en-US.
6. M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal. Band 6, Nummer 8, 08 2016, S. e458,,, .
7. https://www.gemoab.com/advisoryboard Scientific and Strategic Advisory Board
8. https://www.gemoab.com/our-partners Our Partners
9. https://www.uniklinikum-dresden.de/de/das-klinikum/universitaetscentren/universitaets-krebscentrum-ucc/core-units/early-clinical-trials-unit/studien/akute-myeloische-leukaemie/copy_of_Roche%20BH39147-NHL-DLBCL AML: GEM333-01
10. https://clinicaltrials.gov/ct2/show/NCT03516760 Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
11. https://clinicaltrials.gov/ct2/show/NCT03927573 Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker